News Releases

Nov 11, 2021
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
WATERTOWN, Mass. , Nov. 11, 2021 /PRNewswire/ --  Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased
Additional Formats
Oct 04, 2021
Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society
Approximately 50% of treated CRS patients experienced durable symptom improvement six months after treatment with LYR-210 (7500μg) LYR-210 pharmacokinetics indicate a constant and steady daily dose of Mometasone Furoate is delivered to patients LANTERN study manuscript wins ARS Annual Meeting 2021
Additional Formats
Sep 20, 2021
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of
Additional Formats
Sep 13, 2021
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,
Additional Formats
Sep 09, 2021
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Results demonstrate XTreo ™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3
Additional Formats
Displaying 1 - 10 of 28
Print Page
Email Alerts
RSS Feeds
Contact IR
Search
Back to Top